MedTrace Logo

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

NCT03454503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2021-02-23

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the effectiveness and safety of generic imatinib under usual clinical practice in patients of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients in chronic phase (CP) in Egypt

Conditions

  • Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase

Interventions

DRUG

Imatinib

Film coated tablet contains 400 mg imatinib (as mesilate)

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-13
Primary Completion
2020-12-28
Completion
2020-12-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03454503 on ClinicalTrials.gov